Screener
Bioventus BVS Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|
| Other, net | (461) | (412) |
| Net cash from financing activities | (46,576) | (13,716) |
| Effect of exchange rate changes on cash | (978) | 632 |
| Net change in cash and cash equivalents | (21,781) | (8,672) |
| Cash and cash equivalents at the beginning of the period | 51,238 | 41,582 |
| Cash and cash equivalents at the end of the period | $29,457 | $32,910 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Accounts payable for purchase of property, plant and equipment | $136 | $196 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's cash & equivalents?
- Bioventus (BVS) reported cash & equivalents of $29.46M in Q2 2026.
- How has Bioventus's cash & equivalents changed year-over-year?
- Bioventus's cash & equivalents decreased by 10.5% year-over-year, from $32.91M to $29.46M.
- What is the long-term trend for Bioventus's cash & equivalents?
- Over 5 years (2020 to 2025), Bioventus's cash & equivalents has grown at a -10.0% compound annual growth rate (CAGR), from $86.84M to $51.24M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Bioventus's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude